Amodel-based statistic for detecting molecular markers associated with complex survival patterns in early-stage cancer Philippe Broët1,2,3 * and Thierry Moreau4,5 Background: In early-stage of cancer, primary treatment can be considered as effective at eliminating the tumor for a non-negligible proportion of patients whereas for the others it leads to a lower tumor burden and thereby potentially prolonged survival. In this mixed population of patients, it is of great interest to detect complex differences in survival distributions associated with molecular markers that potentially activate latent downstream pathways implicated in tumor progression. Method: We propose a novel model-based score test designed for identifying molecular markers...
Clinical decisions in cancer rely on precisely assessing patient risk. To improve our ability to ide...
Introduction: Currently, there are few markers available which are able to predict who is likely to ...
Purpose: The National Lung Cancer Screening Trial has confirmed that lung cancer mortality can be re...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: In early-stage of cancer, primary treatment ...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
BACKGROUND: There is wide interest in the use of molecular markers for the early detection of cancer...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
International audienceBackground: In genomic medical studies, one of the major objectives is to iden...
A key challenge in genomics is to identify genetic variants that distinguish patients with dif-feren...
The increased availability of ultrahigh-dimensional biomarker data and the high demand of identifyin...
International audienceBACKGROUND: With the growing number of public repositories for high-throughput...
Summary: Identifying biomarkers to predict the clinical outcomes of individual patients is a fundame...
Each cancer is unique: it reflects the underlying genetic make-up of the patient and the stochastic ...
In cancer studies, patients often experience two different types of events: a non-terminal event suc...
Clinical decisions in cancer rely on precisely assessing patient risk. To improve our ability to ide...
Introduction: Currently, there are few markers available which are able to predict who is likely to ...
Purpose: The National Lung Cancer Screening Trial has confirmed that lung cancer mortality can be re...
International audienceUNLABELLED: ABSTRACT: BACKGROUND: In early-stage of cancer, primary treatment ...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
BACKGROUND: There is wide interest in the use of molecular markers for the early detection of cancer...
IntroductionThe aim of this study was to validate a molecular expression signature [cell cycle progr...
International audienceBackground: In genomic medical studies, one of the major objectives is to iden...
A key challenge in genomics is to identify genetic variants that distinguish patients with dif-feren...
The increased availability of ultrahigh-dimensional biomarker data and the high demand of identifyin...
International audienceBACKGROUND: With the growing number of public repositories for high-throughput...
Summary: Identifying biomarkers to predict the clinical outcomes of individual patients is a fundame...
Each cancer is unique: it reflects the underlying genetic make-up of the patient and the stochastic ...
In cancer studies, patients often experience two different types of events: a non-terminal event suc...
Clinical decisions in cancer rely on precisely assessing patient risk. To improve our ability to ide...
Introduction: Currently, there are few markers available which are able to predict who is likely to ...
Purpose: The National Lung Cancer Screening Trial has confirmed that lung cancer mortality can be re...